Not Bad For Scraps

Everyone forgets that Pfizer (PFE) tried to buy AstraZeneca (AZN) for scraps back in 2014. The UK Parliament threw a fit, the deal died, and Wall Street moved on.

Fast forward, AstraZeneca is worth double what Pfizer is. The press still treats it like a mid-tier pharma shop. Meanwhile, it’s running the table in oncology.

If you’re just now noticing the new all-time high, you’re late. But not too late.

AstraZeneca’s climb didn’t come from a single miracle drug or a lucky pandemic windfall. It came from doing the slow, difficult work of rebuilding a pipeline molecule by molecule until the market had no choice but to reprice it.

Nowhere is that more obvious than in oncology, where the company has assembled a constellation of high-conviction products that keep widening their reach.

Imfinzi brought in $1.6 billion last quarter, up 33% year over year, driven not by price but by a flood of new approvals. Lung cancer, bladder cancer, gastric cancer, and gastroesophageal junction tumors all now carry Imfinzi as a legitimate standard-of-care option, supported by large Phase III trials.

The MATTERHORN study alone cut the risk of death by 22% when paired with FLOT chemotherapy. In oncology, shaving 2% or 3% is considered progress. 22% moves markets.

Datroway and Enhertu are the other engines powering AstraZeneca’s new identity.

Enhertu revenue jumped 40% year over year to $714 million in Q3, with room to run, driven by its expansion into six approved HER2 indications.

Datroway is further back in its lifecycle but moving fast, growing 118% and now tracking toward $5 billion in peak annual sales if its triple-negative breast cancer performance continues to hold in broad practice.

It’s unusual for one pharma company to have two ADCs with that kind of trajectory. Read through the industry earnings transcripts, and you can sense the panic. Everyone wants an ADC franchise. AstraZeneca already has one.

Meanwhile, the Street continues to underestimate how diversified AstraZeneca has become.

Cardiometabolic medicine isn’t a side project here. Farxiga pulled in $2.1 billion last quarter with double-digit growth.

Rare diseases are another ballast, with Ultomiris generating $1.2 billion and Soliris right behind it despite the expected sunset. Combined, these franchises add more than $3.3 billion of quarterly revenue outside oncology.

That’s what makes AstraZeneca particularly dangerous to short sellers. Even rough oncology trial results don’t derail the whole machine.

For reference, the company delivered $1.19 of non-GAAP EPS in Q3, up 14% from the prior year and 9% sequentially. Wall Street keeps modeling modest beats. AstraZeneca keeps printing large ones. The pattern is starting to look structural.

The company has topped consensus expectations in 9 of its last 11 quarters. You don’t see that consistency from a legacy pharma operator unless it’s transitioning into something bigger.

The leadership deserves mention. Pascal Soriot took over a stumbling patent-cliff company and traded in the old blockbuster model for a portfolio powered by volume.

Rather than chase a single market-defining drug, AstraZeneca now pushes many assets across many indications. That approach is starting to resemble the way technology platforms scale.

Each successful approval raises the odds of the next one, compounding clinical acceptance, physician familiarity, and formulary placement. The model is difficult to copy unless competitors are willing to rebuild from the ground up.

The only rational pushbacks today are the usual ones. Drugs lose exclusivity. Some late-stage trials miss. Imfinzi plus ceralasertib failed in the LATIFY Phase III, and Soliris revenue came in $15 million shy of expectations.

But when the misses are rounding errors, and the wins are measured in billions, it tells you where the center of gravity now sits.

The market still treats AstraZeneca like the cautious British cousin to faster-talking American peers. But the scoreboard has changed.

Pfizer is cutting costs to offset collapsing COVID revenue. AstraZeneca is using oncology cash flow to expand into gastroesophageal cancers, rare diseases, and immunology.

You rarely see two mega caps cross paths in opposite directions this quickly, and it almost never happens without a takeover bid somewhere in the story.

Pfizer tried to buy AstraZeneca for $118 billion 12 years ago. Today, that number wouldn’t even get them through the lobby. Funny how scraps age.